$CORT generated 6 mentions from 2 distinct FinTwit voices over the past 12 months, with the first mention on 2026-02-05. Adam Feuerstein (@adamfeuerstein) dominated discussion with 5 mentions, while Jacob Plieth (@jacobplieth) contributed 1 mention. The biotech category accounted for all mentions of Corcept Therapeutics during this period.

The most recent activity centered on Lifyorli, $CORT's approved treatment for advanced ovarian cancer. On 2026-03-25, Feuerstein noted FDA approval despite his previous concerns about liver injury risk and higher side effect rates. The following day, discussion shifted to labeling concerns, with Feuerstein characterizing the Lifyorli label as "a safety and drug-interaction horror show" while Plieth questioned differences between prescribing information and the drug's experience in Cushing's disease.